| scholarly article | Q13442814 |
| P50 | author | Massimiliano Gnecchi | Q43088906 |
| Fulvio Morello | Q56951654 | ||
| P2093 | author name string | Lunan Zhang | |
| Victor J Dzau | |||
| Richard E Pratt | |||
| Huamei He | |||
| Olin D Liang | |||
| Joanne S Ingwall | |||
| Luis G Melo | |||
| Nicolas Noiseux | |||
| Hui Mu | |||
| P2860 | cites work | Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells | Q24672061 |
| Bone marrow cells regenerate infarcted myocardium | Q28210640 | ||
| Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation | Q33202256 | ||
| Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart | Q64379356 | ||
| 31P nuclear magnetic resonance spectroscopic imaging of regions of remodeled myocardium in the infarcted rat heart | Q70787324 | ||
| Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts | Q73791469 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mesenchymal stem cell | Q1922379 |
| P304 | page(s) | 367-368 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells | |
| P478 | volume | 11 |
| Q58648634 | Q58648634 |
| Q36971027 | "AKT"ing lessons for stem cells: regulation of cardiac myocyte and progenitor cell proliferation |
| Q36679690 | 3D Spheroid Culture Enhances the Expression of Antifibrotic Factors in Human Adipose-Derived MSCs and Improves Their Therapeutic Effects on Hepatic Fibrosis |
| Q42464603 | 3D spheroid culture enhances survival and therapeutic capacities of MSCs injected into ischemic kidney |
| Q36543846 | 7. Transplantation of undifferentiated, bone marrow-derived stem cells |
| Q38289941 | A Deep Proteome Analysis Identifies the Complete Secretome as the Functional Unit of Human Cardiac Progenitor Cells |
| Q42914922 | A G-CSF functionalized scaffold for stem cells seeding: a differentiating device for cardiac purposes |
| Q90481195 | A New Era of Cardiac Cell Therapy: Opportunities and Challenges |
| Q35621019 | A New Paradigm in Cardiac Regeneration: The Mesenchymal Stem Cell Secretome |
| Q89494255 | A Role for Exosomes in Craniofacial Tissue Engineering and Regeneration |
| Q36632891 | A comparison of the efficacy of transplantation of bone marrow-derived mesenchymal stem cells and unrestricted somatic stem cells on outcome after acute myocardial infarction |
| Q93024988 | A comprehensive, multiscale framework for evaluation of arrhythmias arising from cell therapy in the whole post-myocardial infarcted heart |
| Q34116906 | A crucial role of activin A-mediated growth hormone suppression in mouse and human heart failure |
| Q33701439 | A multistep procedure to prepare pre-vascularized cardiac tissue constructs using adult stem sells, dynamic cell cultures, and porous scaffolds. |
| Q30300274 | A novel cardiac muscle-derived biomaterial reduces dyskinesia and postinfarct left ventricular remodeling in a mouse model of myocardial infarction |
| Q26998969 | A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods |
| Q41965313 | Abi3bp is a multifunctional autocrine/paracrine factor that regulates mesenchymal stem cell biology |
| Q47918808 | Absence of NUCKS augments paracrine effects of mesenchymal stem cells-mediated cardiac protection. |
| Q38657237 | Acellular approaches for regenerative medicine: on the verge of clinical trials with extracellular membrane vesicles? |
| Q33676193 | Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET |
| Q34477403 | Adhesion proteins, stem cells, and arrhythmogenesis |
| Q28071698 | Adipose Tissue-Derived Stem Cells in Regenerative Medicine |
| Q59340395 | Adipose-derived stem cells alleviate liver apoptosis induced by ischemia-reperfusion and laparoscopic hepatectomy in swine |
| Q91799560 | Administration of Interleukin-15 Peptide Improves Cardiac Function in a Mouse Model of Myocardial Infarction |
| Q99234013 | Administration of cardiac mesenchymal cells modulates innate immunity in the acute phase of myocardial infarction in mice |
| Q37698929 | Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review |
| Q37157668 | Adult mesenchymal stromal stem cells for therapeutic applications |
| Q36815983 | Adult stem cells and heart regeneration |
| Q37779933 | Adult stem cells for cardiac tissue engineering |
| Q34295979 | Advanced Donor Age Impairs Bone Marrow Cell Therapeutic Efficacy for Cardiac Disease |
| Q41906508 | Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy |
| Q89142435 | Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes |
| Q92405541 | Age-dependent impairment of adipose-derived stem cells isolated from horses |
| Q31033256 | Age-related changes in rat bone-marrow mesenchymal stem cell plasticity |
| Q59807454 | Aging of mesenchymal stem cells: Implication in regenerative medicine |
| Q35665164 | Aire controls mesenchymal stem cell-mediated suppression in chronic colitis |
| Q35716182 | Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats |
| Q33905832 | Akt1 in the cardiovascular system: friend or foe? |
| Q95841288 | Alginate Formulations: Current Developments in the Race for Hydrogel-Based Cardiac Regeneration |
| Q48548226 | Alginate microencapsulation of human mesenchymal stem cells as a strategy to enhance paracrine-mediated vascular recovery after hindlimb ischaemia. |
| Q37310724 | Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. |
| Q41997489 | Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study. |
| Q50489435 | Amniotic fluid stem cells rescue both in vitro and in vivo growth, innervation, and motility in nitrofen-exposed hypoplastic rat lungs through paracrine effects. |
| Q42949554 | Amplification of coronary arteriogenic capacity of multipotent stromal cells by epidermal growth factor |
| Q34040779 | An acellular biologic scaffold promotes skeletal muscle formation in mice and humans with volumetric muscle loss |
| Q35565809 | An emerging consensus on cardiac regeneration |
| Q42861069 | An imperfect syllogism: granulocyte colony-stimulating factor mobilization and cardiac regeneration |
| Q33505675 | Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice |
| Q36280879 | Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration. |
| Q50947816 | Angiogenic and osteogenic regeneration in rats via calcium phosphate scaffold and endothelial cell co-culture with human bone marrow mesenchymal stem cells (MSCs), human umbilical cord MSCs, human induced pluripotent stem cell-derived MSCs and human |
| Q42513510 | Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis |
| Q42282500 | Annexin-enriched osteoblast-derived vesicles act as an extracellular site of mineral nucleation within developing stem cell cultures |
| Q93006643 | Anti-CD3 Antibody Treatment Reduces Scar Formation in a Rat Model of Myocardial Infarction |
| Q30475341 | Antioxidants improve early survival of cardiomyoblasts after transplantation to the myocardium |
| Q34718264 | Apoptosis of bone marrow mesenchymal stem cells caused by homocysteine via activating JNK signal |
| Q93089068 | Application of Bioengineered Materials in the Surgical Management of Heart Failure |
| Q42542660 | Application of stem cells in orthopedics |
| Q36422761 | Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. |
| Q54650658 | Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating amp-activated protein kinase |
| Q42316372 | Autologous c-Kit+ Mesenchymal Stem Cell Injections Provide Superior Therapeutic Benefit as Compared to c-Kit+ Cardiac-Derived Stem Cells in a Feline Model of Isoproterenol-Induced Cardiomyopathy |
| Q37837891 | Autologous cell therapy for cardiac repair. |
| Q37420332 | Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy |
| Q35621000 | Bcl-xL Genetic Modification Enhanced the Therapeutic Efficacy of Mesenchymal Stem Cell Transplantation in the Treatment of Heart Infarction |
| Q36127774 | Beneficial effects of non-matched allogeneic cord blood mononuclear cells upon patients with idiopathic osteoporosis |
| Q89578028 | Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy |
| Q36793257 | Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells |
| Q36861582 | Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats |
| Q35180158 | Biological approaches to improve skeletal muscle healing after injury and disease |
| Q99578823 | Biomaterials functionalized with MSC secreted extracellular vesicles and soluble factors for tissue regeneration |
| Q53509411 | Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. |
| Q92340278 | Bone Marrow-Derived Mesenchymal Stem Cells Modified with Akt1 Ameliorates Acute Liver GVHD |
| Q91998597 | Bone marrow as a target and accomplice of vascular complications in diabetes |
| Q40348037 | Bone marrow cell transfer in acute myocardial infarction |
| Q33379564 | Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction |
| Q33942087 | Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products |
| Q33853277 | Bone marrow mesenchymal stem cell-derived vascular endothelial growth factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a and miRNA-92a in a rat model of myocardial infarction |
| Q34011512 | Bone marrow mesenchymal stem cells protected post-infarcted myocardium against arrhythmias via reversing potassium channels remodelling |
| Q30523741 | Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation |
| Q34213386 | Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn |
| Q59340606 | Bone marrow mesenchymal stromal cells attenuate silica-induced pulmonary fibrosis potentially by attenuating Wnt/β-catenin signaling in rats |
| Q50688665 | Bone marrow mononuclear cell therapy for patients with cirrhosis: a Phase 1 study. |
| Q37194005 | Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction. |
| Q37951953 | Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential. |
| Q42517934 | Bone marrow stromal cells contribute to bone formation following infusion into femoral cavities of a mouse model of osteogenesis imperfecta. |
| Q38166729 | Bone marrow-derived cell therapy in chagasic cardiac disease: a review of pre-clinical and clinical results |
| Q38233057 | Bone marrow-derived mesenchymal cell differentiation toward myogenic lineages: facts and perspectives. |
| Q30427978 | Bone marrow-derived progenitor cells augment venous remodeling in a mouse dorsal skinfold chamber model |
| Q36804551 | Bone marrow-derived stem cell therapy in ischemic heart disease |
| Q38978163 | Bone regeneration using mesenchymal stem cells: challenges and future perspectives in regenerative surgery |
| Q30557136 | Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms |
| Q38858359 | Brain mesenchymal stem cells: physiology and pathological implications |
| Q36587910 | Breast and abdominal adipose multipotent mesenchymal stromal cells and stage-specific embryonic antigen 4 expression. |
| Q50668745 | C-kit+ cardiac progenitors exhibit mesenchymal markers and preferential cardiovascular commitment. |
| Q41919795 | CCND2 Overexpression Enhances the Regenerative Potency of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Remuscularization of Injured Ventricle |
| Q33713175 | CD133 identifies a human bone marrow stem/progenitor cell sub-population with a repertoire of secreted factors that protect against stroke. |
| Q36023234 | Capturing the stem cell paracrine effect using heparin-presenting nanofibres to treat cardiovascular diseases |
| Q61958028 | Cardiac Cell Therapy: The Next (Re)Generation |
| Q58565104 | Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes |
| Q37371934 | Cardiac cell repair therapy: a clinical perspective |
| Q37273074 | Cardiac cell therapy in vitro: reproducible assays for comparing the efficacy of different donor cells |
| Q37092180 | Cardiac cell-based therapy: cell types and mechanisms of actions |
| Q36406439 | Cardiac cell-repair therapy: clinical issues |
| Q34856239 | Cardiac progenitor cell commitment is inhibited by nuclear Akt expression |
| Q34032940 | Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction |
| Q37253735 | Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease |
| Q33406980 | Cardiac repair with adult bone marrow-derived cells: the clinical evidence |
| Q42575668 | Cardiac stem cell therapy and the promise of heart regeneration |
| Q36267790 | Cardiac stem cells and mechanisms of myocardial regeneration |
| Q41761869 | Cardiac tissue engineering: a reflection after a decade of hurry |
| Q37319214 | Cardiogenic differentiation and transdifferentiation of progenitor cells |
| Q29620480 | Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts |
| Q30362960 | Cardioprotective repair through stem cell-based cardiopoiesis. |
| Q42028739 | Cardiovascular Stem Cells in Regenerative Medicine: Ready for Prime Time? |
| Q37844431 | Cardiovascular magnetic resonance imaging in experimental models |
| Q41367762 | Cardiovascular repair with bone marrow-derived cells |
| Q89862240 | Cell Secretome: Basic Insights and Therapeutic Opportunities for CNS Disorders |
| Q53508391 | Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials. |
| Q57159453 | Cell Therapy for Heart Regeneration: Learning from the Past to Build a Brighter Future |
| Q26765916 | Cell Therapy in Ischemic Heart Disease: Interventions That Modulate Cardiac Regeneration |
| Q42359770 | Cell secretome based drug substances in regenerative medicine: when regulatory affairs meet basic science. |
| Q37444377 | Cell therapies for therapeutic angiogenesis: back to the bench |
| Q39139678 | Cell therapy for GI motility disorders: comparison of cell sources and proposed steps for treating Hirschsprung disease. |
| Q38095938 | Cell therapy for cardiovascular diseases |
| Q27001159 | Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions |
| Q37776514 | Cell therapy for heart failure: the need for a new therapeutic strategy |
| Q38226693 | Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. |
| Q33618626 | Cell therapy for myocardial infarction. |
| Q37696967 | Cell therapy for the treatment of coronary heart disease: a critical appraisal |
| Q33295408 | Cell therapy in congestive heart failure |
| Q37988913 | Cell therapy in the heart |
| Q37863718 | Cell therapy of burns. |
| Q36559155 | Cell therapy: a 21st-century hope for treating cardiovascular disease--what do the next 5 years hold? |
| Q36784068 | Cell tracking and the development of cell-based therapies: a view from the Cardiovascular Cell Therapy Research Network |
| Q36667275 | Cell-based approaches for cardiac repair |
| Q36277263 | Cell-based therapies and imaging in cardiology |
| Q33713519 | Cell-based therapy for heart disease: a clinically oriented perspective |
| Q79579797 | Cell-enhancement strategies for the treatment of ischemic heart disease |
| Q38859871 | Cellular Therapy for Heart Failure. |
| Q34596348 | Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms |
| Q36669952 | Cellular cardiomyoplasty by catheter-based infusion of stem cells in clinical settings |
| Q38027920 | Cellular cardiomyoplasty: current state of the field. |
| Q42875580 | Cellular encapsulation enhances cardiac repair |
| Q26863444 | Cellular therapy promotes endogenous stem cell repair |
| Q84606827 | Central Role for Disabled-2 in Mesenchymal Stem Cardiac Protein Expression and Functional Consequences After Engraftment in Acute Myocardial Infarction |
| Q37731741 | Challenges in the translation of cardiovascular cell therapy |
| Q36011869 | Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial |
| Q34660008 | Characterization of Nestin-positive stem Leydig cells as a potential source for the treatment of testicular Leydig cell dysfunction |
| Q57467367 | Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases |
| Q47191632 | Clinical potential of mesenchymal stem/stromal cell-derived extracellular vesicles |
| Q40250933 | Clinical trials in stem cell therapy: pitfalls and lessons for the future |
| Q83973667 | Co-culture of mesenchymal stem cells with umbilical vein endothelial cells under hypoxic condition |
| Q36464522 | Co-culture with periodontal ligament stem cells enhanced osteoblastic differentiation of MC3T3-E1 cells and osteoclastic differentiation of RAW264.7 cells |
| Q36127880 | Coculture with hematopoietic stem cells protects cardiomyocytes against apoptosis via paracrine activation of AKT |
| Q38926005 | Combination of miRNA499 and miRNA133 exerts a synergic effect on cardiac differentiation. |
| Q34046814 | Combinatorial G-CSF/AMD3100 treatment in cardiac repair after myocardial infarction |
| Q50547590 | Combined MSC-Secreted Factors and Neural Stem Cell Transplantation Promote Functional Recovery of PD Rats. |
| Q35097344 | Comparison of angiogenic, cytoprotective, and immunosuppressive properties of human amnion- and chorion-derived mesenchymal stem cells |
| Q46775271 | Comparison of the effects of human dental pulp stem cells and human bone marrow-derived mesenchymal stem cells on ischemic human astrocytes in vitro |
| Q37714135 | Comparison of the proliferation, migration and angiogenic properties of human amniotic epithelial and mesenchymal stem cells and their effects on endothelial cells |
| Q48100040 | Concise Review: Extracellular Vesicles Overcoming Limitations of Cell Therapies in Ischemic Stroke. |
| Q38432643 | Concise Review: MSC-Derived Exosomes for Cell-Free Therapy |
| Q38583455 | Concise Review: Pluripotent Stem Cell-Derived Cardiac Cells, A Promising Cell Source for Therapy of Heart Failure: Where Do We Stand? |
| Q52582832 | Concise Review: Rational Use of Mesenchymal Stem Cells in the Treatment of Ischemic Heart Disease. |
| Q42221122 | Conditioned medium derived from mesenchymal stem cells overexpressing HPV16 E6E7 dramatically improves ischemic limb |
| Q35552105 | Conditioned medium from human amniotic mesenchymal stromal cells limits infarct size and enhances angiogenesis |
| Q54699022 | Connexin43 promotes survival of mesenchymal stem cells in ischaemic heart. |
| Q36801683 | Cord lining-mesenchymal stem cells graft supplemented with an omental flap induces myocardial revascularization and ameliorates cardiac dysfunction in a rat model of chronic ischemic heart failure |
| Q53271039 | Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization. |
| Q64274926 | Cortical Bone Derived Stem Cells for Cardiac Wound Healing |
| Q42836395 | Cortical bone-derived stem cells: a novel class of cells for myocardial protection |
| Q55435775 | Current Progress in the Rejuvenation of Aging Stem/Progenitor Cells for Improving the Therapeutic Effectiveness of Myocardial Repair. |
| Q38090542 | Current status of cell-based therapy for heart failure |
| Q27004753 | Current stem cell delivery methods for myocardial repair |
| Q46044960 | Cyclosporin A pre-incubation attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells |
| Q53628210 | Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. |
| Q39824359 | Defining human mesenchymal stem cell efficacy in vivo. |
| Q55052510 | Derivation and characterization of human fetal MSCs: an alternative cell source for large-scale production of cardioprotective microparticles. |
| Q82662246 | Derivation of a cardiopoietic population from human mesenchymal stem cells yields cardiac progeny |
| Q35788661 | Development of mRuby2-Transfected C3H10T1/2 Fibroblasts for Musculoskeletal Tissue Engineering. |
| Q28080127 | Developmental origin and lineage plasticity of endogenous cardiac stem cells |
| Q30428895 | Diabetes-associated macrovascular complications: cell-based therapy a new tool? |
| Q35204126 | Diabetic Mesenchymal Stem Cells Are Ineffective for Improving Limb Ischemia Due to Their Impaired Angiogenic Capability. |
| Q47271643 | Differences in Stem Cell Processing Lead to Distinct Secretomes Secretion-Implications for Differential Results of Previous Clinical Trials of Stem Cell Therapy for Myocardial Infarction. |
| Q60300689 | Different pro-angiogenic potential of γ-irradiated PBMC-derived secretome and its subfractions |
| Q37568644 | Direct contact of umbilical cord blood endothelial progenitors with living cardiac tissue is a requirement for vascular tube-like structures formation. |
| Q64277481 | Donation of mitochondria by iPSC-derived mesenchymal stem cells protects retinal ganglion cells against mitochondrial complex I defect-induced degeneration |
| Q29304005 | Donor Myocardial Infarction Impairs the Therapeutic Potential of Bone Marrow Cells by an Interleukin-1-Mediated Inflammatory Response |
| Q34017342 | Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction |
| Q37608599 | Drawbacks to stem cell therapy in cardiovascular diseases |
| Q36333354 | Drosha regulates hMSCs cell cycle progression through a miRNA independent mechanism. |
| Q37420535 | Dying blood mononuclear cell secretome exerts antimicrobial activity. |
| Q37253137 | Dynamic Tracking of Injected Mesenchymal Stem Cells after Myocardial Infarction in Rats: A Serial 7T MRI Study. |
| Q93023528 | Dynamic secretome of bone marrow-derived stromal cells reveals a cardioprotective biochemical cocktail |
| Q45074078 | ENaCs as Both Effectors and Regulators of MiRNAs in Lung Epithelial Development and Regeneration |
| Q33862492 | Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction |
| Q42292968 | Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis |
| Q50765097 | Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation. |
| Q38730864 | Eat, breathe, ROS: controlling stem cell fate through metabolism |
| Q42119570 | Effect of Local Anesthetics on Human Mesenchymal Stromal Cell Secretion |
| Q64097626 | Effect of cell culture density on dental pulp-derived mesenchymal stem cells with reference to osteogenic differentiation |
| Q34062678 | Effect of disruption of Akt-1 of lin(-)c-kit(+) stem cells on myocardial performance in infarcted heart |
| Q42556398 | Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin. |
| Q54353050 | Effects of mesenchymal stem cells on matrix metalloproteinase synthesis in cardiac fibroblasts. |
| Q84367668 | Effects of stromal-derived factor 1 preconditioning on apoptosis of rat bone mesenchymal stem cells |
| Q39246460 | Effects of transplanted bone-marrow-derived mesenchymal stem cells in animal models of acute hepatitis |
| Q42117511 | Efficacy and Durability in Direct Labeling of Mesenchymal Stem Cells Using Ultrasmall Superparamagnetic Iron Oxide Nanoparticles with Organosilica, Dextran, and PEG Coatings. |
| Q50981151 | Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells. |
| Q36995124 | Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions |
| Q37388612 | Embryonic stem cells in cardiac repair and regeneration |
| Q36920724 | Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology |
| Q36657651 | Empowering Adult Stem Cells for Myocardial Regeneration V2.0: Success in Small Steps |
| Q34999840 | Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs |
| Q35228327 | Encapsulated mesenchymal stromal cells for in vivo transplantation |
| Q58130049 | Engineered Exosomes With Ischemic Myocardium-Targeting Peptide for Targeted Therapy in Myocardial Infarction |
| Q92328763 | Engineering Functional Cardiac Tissues for Regenerative Medicine Applications |
| Q59064296 | Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia |
| Q24677311 | Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium |
| Q33722181 | Enhanced Cardioprotection by Human Endometrium Mesenchymal Stem Cells Driven by Exosomal MicroRNA-21. |
| Q50516456 | Enhanced therapeutic effects of mesenchymal stem cells on myocardial infarction by ischemic postconditioning through paracrine mechanisms in rats. |
| Q36956699 | Erythropoietin expands a stromal cell population that can mediate renoprotection |
| Q46568661 | Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia |
| Q36729333 | Evaluation of neural plasticity in adult stem cells |
| Q47438101 | Evolving cell-based therapies for heart failure patients |
| Q45880351 | Ex vivo Akt/HO-1 gene therapy to human endothelial progenitor cells enhances myocardial infarction recovery |
| Q35943572 | Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress |
| Q36116162 | Exercise-induced Signals for Vascular Endothelial Adaptations: Implications for Cardiovascular Disease |
| Q34397290 | Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction |
| Q88483632 | Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells |
| Q42751931 | Exosomes as potential alternatives to stem cell therapy in mediating cardiac regeneration |
| Q51545509 | Exosomes from Cardiomyocyte Progenitor Cells and Mesenchymal Stem Cells Stimulate Angiogenesis Via EMMPRIN. |
| Q39319239 | Exosomes in Cardiovascular Medicine. |
| Q50434191 | Experimental and Computational Insight Into Human Mesenchymal Stem Cell Paracrine Signaling and Heterocellular Coupling Effects on Cardiac Contractility and Arrhythmogenicity. |
| Q99565662 | Experimental artefacts can lead to misattribution of bioactivity from soluble mesenchymal stem cell paracrine factors to extracellular vesicles |
| Q42775592 | Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition |
| Q47188892 | Exploiting Advanced Hydrogel Technologies to Address Key Challenges in Regenerative Medicine |
| Q42592803 | Exploiting paracrine mechanisms of tissue regeneration to repair damaged organs. |
| Q28073078 | Exploring pericyte and cardiac stem cell secretome unveils new tactics for drug discovery |
| Q84647901 | Expression and secretion of interleukin‐1β, tumour necrosis factor‐α and interleukin‐10 by hypoxia‐ and serum‐deprivation‐stimulated mesenchymal stem cells |
| Q90484318 | Extracellular Vesicles Derived From Mesenchymal Stem Cells (MSC) in Regenerative Medicine: Applications in Skin Wound Healing |
| Q64994192 | Extracellular Vesicles Derived from Hypoxic Human Mesenchymal Stem Cells Attenuate GSK3β Expression via miRNA-26a in an Ischemia-Reperfusion Injury Model. |
| Q59335809 | Extracellular Vesicles in Joint Disease and Therapy |
| Q38180964 | Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages |
| Q49183974 | Extracellular vesicles and cardiovascular disease therapy |
| Q38241188 | Extracellular vesicles as therapeutic tools in cardiovascular diseases |
| Q64287227 | Extracellular vesicles from regenerative human cardiac cells act as potent immune modulators by priming monocytes |
| Q39115035 | Extracellular vesicles in coronary artery disease. |
| Q46268171 | Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. |
| Q47304481 | Extracellular vesicles, exosomes and shedding vesicles in regenerative medicine - a new paradigm for tissue repair. |
| Q38098874 | Extracellular vesicles: biology and emerging therapeutic opportunities. |
| Q26784524 | FGF21 and Cardiac Physiopathology |
| Q34369903 | Factors Released from Embryonic Stem Cells Stimulate c-kit-FLK-1(+ve) Progenitor Cells and Enhance Neovascularization |
| Q36844587 | Factors released from embryonic stem cells inhibit apoptosis in H9c2 cells through PI3K/Akt but not ERK pathway |
| Q39633829 | Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells |
| Q46527697 | Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. |
| Q90414200 | Five Decades Later, Are Mesenchymal Stem Cells Still Relevant? |
| Q33471002 | Focused ultrasound-induced stimulation of microbubbles augments site-targeted engraftment of mesenchymal stem cells after acute myocardial infarction |
| Q37184799 | Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart |
| Q50977973 | Functional and bioenergetic modulations in the infarct border zone following autologous mesenchymal stem cell transplantation. |
| Q42079587 | Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy. |
| Q51621930 | Functional impact of targeted closed-chest transplantation of bone marrow cells in rats with acute myocardial ischemia/reperfusion injury. |
| Q34343125 | Fused X-ray and MR imaging guidance of intrapericardial delivery of microencapsulated human mesenchymal stem cells in immunocompetent swine |
| Q57177288 | Future Perspectives on the Role of Stem Cells and Extracellular Vesicles in Vascular Tissue Regeneration |
| Q36227832 | G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis |
| Q37470623 | Gene and cell therapy for heart failure |
| Q24632135 | Gene therapy for ischemic heart disease |
| Q36673719 | Gene-modified mesenchymal stem cells protect against radiation-induced lung injury |
| Q38783991 | Generation of clinical-grade functional cardiomyocytes from human embryonic stem cells in chemically defined conditions |
| Q39136745 | Generation of induced cardiac progenitor cells via somatic reprogramming |
| Q34298871 | Genetic Engineering of Mesenchymal Stem Cells and Its Application in Human Disease Therapy |
| Q37294352 | Genetic engineering and stem cells: combinatorial approaches for cardiac cell therapy |
| Q33734413 | Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles |
| Q33907615 | Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium |
| Q36366735 | Genetically Engineered Mesenchymal Stem Cells Influence Gene Expression in Donor Cardiomyocytes and the Recipient Heart |
| Q37395438 | Genomic profiling of mesenchymal stem cells. |
| Q46247702 | Geraniin protects bone marrow‑derived mesenchymal stem cells against hydrogen peroxide‑induced cellular oxidative stress in vitro |
| Q53055138 | Granulocyte-colony stimulating factor reduces cardiomyocyte apoptosis and ameliorates diastolic dysfunction in Otsuka Long-Evans Tokushima Fatty rats. |
| Q37705248 | Graphite oxide nanoparticles with diameter greater than 20 nm are biocompatible with mouse embryonic stem cells and can be used in a tissue engineering system |
| Q28302576 | HASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotection |
| Q34769978 | HDAC inhibition elicits myocardial protective effect through modulation of MKK3/Akt-1. |
| Q35804026 | Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease |
| Q93197900 | Healing the Broken Heart; The Immunomodulatory Effects of Stem Cell Therapy |
| Q57395528 | Heart failure and regenerative cardiology |
| Q28533775 | Heme oxygenase-1 prevents cardiac dysfunction in streptozotocin-diabetic mice by reducing inflammation, oxidative stress, apoptosis and enhancing autophagy |
| Q36141205 | How mesenchymal stem cells interact with tissue immune responses |
| Q34012519 | Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action |
| Q88239142 | Human ISL1+ Ventricular Progenitors Self-Assemble into an In Vivo Functional Heart Patch and Preserve Cardiac Function Post Infarction |
| Q47590766 | Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Encapsulating Bioactive Hydrogels Improve Rat Heart Function Post Myocardial Infarction |
| Q53195886 | Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats. |
| Q44080664 | Human adipose tissue-derived stem cells protect impaired cardiomyocytes from hypoxia/reoxygenation injury through hypoxia-induced paracrine mechanism |
| Q47245780 | Human cord blood cells and myocardial infarction: effect of dose and route of administration on infarct size |
| Q33758841 | Human cord blood progenitors with high aldehyde dehydrogenase activity improve vascular density in a model of acute myocardial infarction. |
| Q82233564 | Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction |
| Q38139850 | Human mesenchymal stem cells and their paracrine factors for the treatment of brain tumors |
| Q53087426 | Human mesenchymal stem cells attenuate pulmonary hypertension induced by prenatal lipopolysaccharide treatment in rats. |
| Q34051561 | Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease |
| Q36857939 | Human placental multipotent mesenchymal stromal cells modulate placenta angiogenesis through Slit2-Robo signaling |
| Q24534272 | Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice |
| Q33807191 | Human umbilical cord blood mononuclear cell transplantation in rats with intrinsic sphincter deficiency |
| Q36791214 | Human umbilical cord blood mononuclear cells and chorionic plate-derived mesenchymal stem cells promote axon survival in a rat model of optic nerve crush injury |
| Q51775681 | Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy. |
| Q36659304 | Hyaluronan enhances bone marrow cell therapy for myocardial repair after infarction |
| Q42242902 | Hypoxia Pre-Conditioned Embryonic Mesenchymal Stem Cell Secretome Reduces IL-10 Production by Peripheral Blood Mononuclear Cells |
| Q42773071 | Hypoxia-pretreated human MSCs attenuate acute kidney injury through enhanced angiogenic and antioxidative capacities |
| Q60048546 | Hypoxic Preconditioned Mesenchymal Stromal Cell Therapy in a Rat Model of Renal Ischemia-reperfusion Injury: Development of Optimal Protocol to Potentiate Therapeutic Efficacy |
| Q30539770 | Hypoxic conditioning enhances the angiogenic paracrine activity of human adipose-derived stem cells. |
| Q24603371 | Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells |
| Q33972581 | IL-15: a novel prosurvival signaling pathway in cardiomyocytes. |
| Q52731378 | Imaging cellular pharmacokinetics of 18F-FDG and 6-NBDG uptake by inflammatory and stem cells. |
| Q30494736 | Imaging survival and function of transplanted cardiac resident stem cells |
| Q36703067 | Immune regulation by mesenchymal stem cells: two sides to the coin |
| Q37606564 | Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells |
| Q27004487 | Immunobiology of mesenchymal stem cells |
| Q36174278 | Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells |
| Q94503661 | Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application |
| Q51714776 | Impact of different bone marrow cell preparations on left ventricular remodelling after experimental myocardial infarction. |
| Q42284739 | Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology |
| Q46685771 | Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy |
| Q54423753 | Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. |
| Q34753654 | Improved survival of mesenchymal stromal cell after hypoxia preconditioning: Role of oxidative stress |
| Q91737517 | Improved therapeutic potential of MSCs by genetic modification |
| Q35163294 | Improvement of cardiac function by placenta-derived mesenchymal stem cells does not require permanent engraftment and is independent of the insulin signaling pathway |
| Q35687572 | Improving the Post-Stroke Therapeutic Potency of Mesenchymal Multipotent Stromal Cells by Cocultivation With Cortical Neurons: The Role of Crosstalk Between Cells |
| Q35855818 | In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. |
| Q91878243 | In vivo priming of human mesenchymal stem cells with hepatocyte growth factor-engineered mesenchymal stem cells promotes therapeutic potential for cardiac repair |
| Q38726132 | Individual evaluation of cardiac marker expression and self-beating during cardiac differentiation of P19CL6 cells on different culture substrates. |
| Q48752307 | Individualized stem cell therapy |
| Q39548257 | Induced pluripotent stem (iPS) cells repair and regenerate infarcted myocardium |
| Q90053560 | Induced pluripotent stem cell-derived tenocyte-like cells promote the regeneration of injured tendons in mice |
| Q34454918 | Induced pluripotent stem cells without c-Myc ameliorate retinal oxidative damage via paracrine effects and reduced oxidative stress in rats |
| Q49617810 | Injectable co-gels of collagen and decellularized vascular matrix improve MSC-based therapy for acute kidney injury |
| Q50937837 | Injection of basic fibroblast growth factor together with adipose-derived stem cell transplantation: improved cardiac remodeling and function in myocardial infarction. |
| Q33433387 | Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy |
| Q27338187 | Intra-myocardial injection of both growth factors and heart derived Sca-1+/CD31- cells attenuates post-MI LV remodeling more than does cell transplantation alone: neither intervention enhances functionally significant cardiomyocyte regeneration |
| Q37766197 | Intramyocardial navigation and mapping for stem cell delivery. |
| Q90727813 | Intraportally delivered stem cell spheroids localize in the liver and protect hepatocytes against GalN/LPS-induced fulminant hepatic toxicity |
| Q42659946 | Is biological repair of heart on the horizon? |
| Q27322292 | Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22 |
| Q51313309 | Isolation and Characterization of Exosome from Human Embryonic Stem Cell-Derived C-Myc-Immortalized Mesenchymal Stem Cells. |
| Q58226894 | Isolation and Characterization of Extracellular Vesicles in Stem Cell-Related Studies |
| Q50053575 | Isolation and characterization of mesenchymal stem cells from human fetus heart |
| Q36691627 | Isolation and expansion of resident cardiac progenitor cells. |
| Q27010386 | Kallikrein-kinin in stem cell therapy |
| Q46754972 | Lactate modulates gene expression in human mesenchymal stem cells |
| Q51468945 | Laminin α2-secreting fibroblasts enhance the therapeutic effect of skeletal myoblast sheets. |
| Q33611657 | Learning from Mother Nature: Innovative Tools to Boost Endogenous Repair of Critical or Difficult-to-Heal Large Tissue Defects |
| Q36111569 | Lipopolysaccharide treatment induces genome-wide pre-mRNA splicing pattern changes in mouse bone marrow stromal stem cells |
| Q91939151 | Lipopolysaccharides Improve Mesenchymal Stem Cell-Mediated Cardioprotection by MyD88 and stat3 Signaling in a Mouse Model of Cardiac Ischemia/Reperfusion Injury |
| Q36108438 | Liver epithelial cells proliferate under hypoxia and protect the liver from ischemic injury via expression of HIF-1 alpha target genes |
| Q37355668 | Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function |
| Q30573375 | Local injection of autologous bone marrow cells to regenerate muscle in patients with traumatic brachial plexus injury: a pilot study. |
| Q37562012 | Locally delivered growth factor enhances the angiogenic efficacy of adipose-derived stromal cells transplanted to ischemic limbs |
| Q42039222 | Long Term Study of Protective Mechanisms of Human Adipose Derived Mesenchymal Stem Cells on Cisplatin Induced Kidney injury in Sprague-Dawley Rats |
| Q37175477 | Long-term functional improvement and gene expression changes after bone marrow-derived multipotent progenitor cell transplantation in myocardial infarction |
| Q37471408 | Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure |
| Q37421053 | MEK, p38, and PI-3K mediate cross talk between EGFR and TNFR in enhancing hepatocyte growth factor production from human mesenchymal stem cells. |
| Q34370097 | MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy |
| Q34962330 | MSCs transplantation with application of G-CSF reduces apoptosis or increases VEGF in rabbit model of myocardial infarction |
| Q51201458 | Magnetic targeting of human mesenchymal stem cells with internalized superparamagnetic iron oxide nanoparticles. |
| Q35030040 | Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. |
| Q53576712 | Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. |
| Q42918845 | Mechanisms of cell therapy for clinical investigations: an urgent need for large-animal models |
| Q28079649 | Mechanisms of mesenchymal stem/stromal cell function |
| Q40274980 | Melatonin facilitates adipose-derived mesenchymal stem cells to repair the murine infarcted heart via the SIRT1 signaling pathway |
| Q88952347 | Mesenchymal Stem Cell Paracrine Factors in Vascular Repair and Regeneration |
| Q39223572 | Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications |
| Q57823788 | Mesenchymal Stem Cell-Mediated Autophagy Inhibition |
| Q34763616 | Mesenchymal Stem Cells Ameliorate Atherosclerotic Lesions via Restoring Endothelial Function |
| Q36074040 | Mesenchymal Stem Cells Improve Heart Rate Variability and Baroreflex Sensitivity in Rats with Chronic Heart Failure |
| Q42945928 | Mesenchymal Stem Cells and Cardiomyocytes Interplay to Prevent Myocardial Hypertrophy |
| Q47146529 | Mesenchymal Stem Cells in Cardiology |
| Q39419410 | Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles and Their Potential as Novel Immunomodulatory Therapeutic Agents |
| Q60046871 | Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning |
| Q91899785 | Mesenchymal Stromal Cell-Based Bone Regeneration Therapies: From Cell Transplantation and Tissue Engineering to Therapeutic Secretomes and Extracellular Vesicles |
| Q39781977 | Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia |
| Q91695791 | Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review |
| Q57110619 | Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges |
| Q57805266 | Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms |
| Q37900300 | Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease |
| Q39297520 | Mesenchymal stem cell secreted platelet derived growth factor exerts a pro-migratory effect on resident Cardiac Atrial appendage Stem Cells |
| Q24651962 | Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs |
| Q38004307 | Mesenchymal stem cell therapy for heart disease. |
| Q35889077 | Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine |
| Q43070723 | Mesenchymal stem cell-derived IL-10 and recovery from infarction: a third pitch for the chord |
| Q38670442 | Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases |
| Q90116025 | Mesenchymal stem cell-derived exosomes do not promote the proliferation of cancer cells in vitro |
| Q59336133 | Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs |
| Q44124588 | Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo |
| Q33300346 | Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure |
| Q33765470 | Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration |
| Q58136326 | Mesenchymal stem cells |
| Q26753086 | Mesenchymal stem cells (MSCs) as skeletal therapeutics - an update |
| Q61448396 | Mesenchymal stem cells alleviate the early brain injury of subarachnoid hemorrhage partly by suppression of Notch1-dependent neuroinflammation: involvement of Botch |
| Q35862434 | Mesenchymal stem cells and cardiac repair. |
| Q37982370 | Mesenchymal stem cells and cardiovascular disease: a bench to bedside roadmap |
| Q38816740 | Mesenchymal stem cells and vascular regeneration. |
| Q34349428 | Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery |
| Q44774171 | Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions |
| Q28566510 | Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6 |
| Q36901349 | Mesenchymal stem cells for the treatment of heart failure. |
| Q38214090 | Mesenchymal stem cells for treatment of myocardial infarction. |
| Q90412540 | Mesenchymal stem cells from different sources and their derived exosomes: A pre-clinical perspective |
| Q35009828 | Mesenchymal stem cells improve wound healing in vivo via early activation of matrix metalloproteinase-9 and vascular endothelial growth factor |
| Q37169180 | Mesenchymal stem cells in cancer |
| Q37142817 | Mesenchymal stem cells in tissue repair |
| Q44592644 | Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation |
| Q39298884 | Mesenchymal stem cells overexpressing GCP-2 improve heart function through enhanced angiogenic properties in a myocardial infarction model |
| Q37376894 | Mesenchymal stem cells protect podocytes from apoptosis induced by high glucose via secretion of epithelial growth factor |
| Q34053510 | Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts |
| Q26799013 | Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities |
| Q90175439 | Mesenchymal stem cells secretome: current trends and future challenges |
| Q85022401 | Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes |
| Q98291527 | Mesenchymal stem cells to treat liver diseases |
| Q34157101 | Mesenchymal stem cells, not conditioned medium, contribute to kidney repair after ischemia-reperfusion injury |
| Q37762880 | Mesenchymal stem cells: Mechanisms of immunomodulation and homing |
| Q37724579 | Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair |
| Q26865070 | Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease |
| Q47694971 | Mesenchymal stromal cell phenotype is not influenced by confluence during culture expansion |
| Q38014753 | Mesenchymal stromal cells (MSCs): science and f(r)iction |
| Q48684091 | Mesenchymal stromal cells rescue cortical neurons from apoptotic cell death in an in vitro model of cerebral ischemia |
| Q38499617 | Mesenchymal stromal cells to halt the progression of type 1 diabetes? |
| Q92514773 | Methods for loading therapeutics into extracellular vesicles and generating extracellular vesicles mimetic-nanovesicles |
| Q41984743 | MiR-155 inhibits cell migration of human cardiomyocyte progenitor cells (hCMPCs) via targeting of MMP-16. |
| Q28116144 | MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1 |
| Q35003611 | Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy |
| Q35754348 | Microfluidic Single-Cell Analysis of Transplanted Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes After Acute Myocardial Infarction |
| Q38184460 | Microvesicles and exosomes for intracardiac communication |
| Q37686479 | Microvesicles as mediators of tissue regeneration |
| Q92523675 | Mircrining the injured heart with stem cell-derived exosomes: an emerging strategy of cell-free therapy |
| Q99726354 | Mitochondrial donation in translational medicine; from imagination to reality |
| Q30476644 | Mitochondrial transfer between cells can rescue aerobic respiration |
| Q30836161 | Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage |
| Q52605943 | Modularized Extracellular Vesicles: The Dawn of Prospective Personalized and Precision Medicine. |
| Q42462379 | Modulation of hepatic mitochondrial energy efficiency with age. |
| Q36480080 | Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy |
| Q37808269 | Molecular physiology of cardiac regeneration |
| Q35176487 | Mononuclear cell secretome protects from experimental autoimmune myocarditis |
| Q37678413 | More insight into mesenchymal stem cells and their effects inside the body |
| Q33722504 | Multimodal Delivery of Isogenic Mesenchymal Stem Cells Yields Synergistic Protection from Retinal Degeneration and Vision Loss |
| Q51069965 | Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis. |
| Q42853310 | Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment |
| Q42407370 | Multipotent stem cells in cardiac regenerative therapy |
| Q35843862 | Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response |
| Q36659319 | Muscle-derived stem cell sheets support pump function and prevent cardiac arrhythmias in a model of chronic myocardial infarction. |
| Q37352442 | Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation |
| Q24314350 | Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction |
| Q36908289 | Myocardial AKT: the omnipresent nexus |
| Q42015303 | Myocardial injection with GSK-3β-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. |
| Q36247746 | Myocardial regenerative properties of macrophage populations and stem cells. |
| Q33635730 | Myocardial survival signaling in response to stem cell transplantation |
| Q33746524 | Myocardial transfection of hypoxia-inducible factor-1α and co-transplantation of mesenchymal stem cells enhance cardiac repair in rats with experimental myocardial infarction |
| Q35665230 | N-cadherin determines individual variations in the therapeutic efficacy of human umbilical cord blood-derived mesenchymal stem cells in a rat model of myocardial infarction |
| Q38235920 | Nanoparticles and stem cells - has targeted therapy for aneurysms finally arrived? |
| Q46984458 | Nanotubular crosstalk with distressed cardiomyocytes stimulates the paracrine repair function of mesenchymal stem cells. |
| Q96136503 | Nanovesicles derived from iron oxide nanoparticles-incorporated mesenchymal stem cells for cardiac repair |
| Q96127279 | Native and bioengineered extracellular vesicles for cardiovascular therapeutics |
| Q38155429 | Natural history of mesenchymal stem cells, from vessel walls to culture vessels. |
| Q34245510 | Netrin-1 ameliorates myocardial infarction-induced myocardial injury: mechanisms of action in rats and diabetic mice |
| Q30361288 | New Delivery Systems of Stem Cells for Vascular Regeneration in Ischemia |
| Q38129057 | Non-invasive in-vivo imaging of stem cells after transplantation in cardiovascular tissue |
| Q37907966 | Noninvasive stem cell tracking |
| Q47713030 | Notch activation enhances lineage commitment and protective signaling in cardiac progenitor cells. |
| Q91715702 | Novel Evidence of the Increase in Angiogenic Factor Plasma Levels after Lineage-Negative Stem/Progenitor Cell Intracoronary Infusion in Patients with Acute Myocardial Infarction |
| Q37792416 | Novel Therapies in Childhood Heart Failure: Today and Tomorrow |
| Q21999280 | Novel mechanism for mesenchymal stem cells in attenuating peritoneal adhesion: accumulating in the lung and secreting tumor necrosis factor α-stimulating gene-6 |
| Q50848438 | Optimization of Mesenchymal Stem Cells to Increase Their Therapeutic Potential. |
| Q93069246 | Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction |
| Q38005087 | Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step. |
| Q79438588 | Optimizing adult mesenchymal stem cells for heart repair |
| Q37786701 | Optimizing stem cell function for the treatment of ischemic heart disease |
| Q38982831 | Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology |
| Q42175191 | Ox-LDL modifies the behaviour of bone marrow stem cells and impairs their endothelial differentiation via inhibition of Akt phosphorylation |
| Q27318224 | Paracrine Factors from Irradiated Peripheral Blood Mononuclear Cells Improve Skin Regeneration and Angiogenesis in a Porcine Burn Model |
| Q46362410 | Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair |
| Q42541819 | Paracrine effects of TLR4-polarised mesenchymal stromal cells are mediated by extracellular vesicles |
| Q34700487 | Paracrine effects of bone marrow soup restore organ function, regeneration, and repair in salivary glands damaged by irradiation |
| Q39068025 | Paracrine factors of human mesenchymal stem cells increase wound closure and reduce reactive oxygen species production in a traumatic brain injury in vitro model |
| Q29620571 | Paracrine mechanisms in adult stem cell signaling and therapy |
| Q38107063 | Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. |
| Q34494230 | Paracrine mechanisms of stem cell reparative and regenerative actions in the heart |
| Q36547431 | Paracrine release from nonviral engineered adipose-derived stem cells promotes endothelial cell survival and migration in vitro |
| Q38136924 | Patching the heart: cardiac repair from within and outside |
| Q28071643 | Peripheral blood mononuclear cell secretome for tissue repair |
| Q37467729 | Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease). |
| Q35242096 | Phenotypic and functional characterization of human bone marrow stromal cells in hollow-fibre bioreactors |
| Q58093950 | Pilot Production of Mesenchymal Stem/Stromal Freeze-Dried Secretome for Cell-Free Regenerative Nanomedicine: A Validated GMP-Compliant Process |
| Q37404197 | Platelet rich plasma clot releasate preconditioning induced PI3K/AKT/NFκB signaling enhances survival and regenerative function of rat bone marrow mesenchymal stem cells in hostile microenvironments |
| Q51003781 | Platelet-derived growth factor-BB enhances MSC-mediated cardioprotection via suppression of miR-320 expression. |
| Q36855438 | Pluripotent stem cells for cardiac regeneration: overview of recent advances & emerging trends |
| Q34791203 | Points to Consider in Designing Mesenchymal Stem Cell-Based Clinical Trials |
| Q33994997 | Postinfarct intramyocardial injection of mesenchymal stem cells pretreated with TGF-alpha improves acute myocardial function. |
| Q45215541 | Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1. |
| Q92394640 | Potential Clinical Applications of Stem Cells in Regenerative Medicine |
| Q38160455 | Potential and clinical utility of stem cells in cardiovascular disease. |
| Q42727547 | Potential of mesenchymal stem cells in the repair of tubular injury |
| Q88219970 | Preclinical Studies of Stem Cell Therapy for Heart Disease |
| Q55564081 | Preconditioning in regenerative medicine. |
| Q93366161 | Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury |
| Q93066172 | Priming with erythropoietin enhances cell survival and angiogenic effect of mesenchymal stem cell implantation in rat limb ischemia |
| Q34245487 | Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming |
| Q42499130 | Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD. |
| Q35296718 | Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1. |
| Q36108608 | Progenitor/stem cell transplantation for repair of myocardial infarction: Hype or hope? |
| Q27001064 | Progenitors for the corneal endothelium and trabecular meshwork: a potential source for personalized stem cell therapy in corneal endothelial diseases and glaucoma |
| Q36327823 | Progress and prospects: cell based regenerative therapy for cardiovascular disease. |
| Q33858319 | Proinflammatory stem cell signaling in cardiac ischemia |
| Q35224444 | Prolonged hypoxia induces monocarboxylate transporter-4 expression in mesenchymal stem cells resulting in a secretome that is deleterious to cardiovascular repair |
| Q46728724 | Protective Effect of Intravitreal Administration of Exosomes Derived from Mesenchymal Stem Cells on Retinal Ischemia. |
| Q33489764 | Protective paracrine effect of mesenchymal stem cells on cardiomyocytes |
| Q34978109 | Protein signaling networks from single cell fluctuations and information theory profiling |
| Q91760354 | Proteomic analysis of the secretome of adipose tissue-derived murine mesenchymal cells overexpressing telomerase and myocardin |
| Q89719762 | Purity Determines the Effect of Extracellular Vesicles Derived from Mesenchymal Stromal Cells |
| Q40238928 | REPAIR-AMI: stem cells for acute myocardial infarction |
| Q37807086 | REVIEW: Stem Cell Therapy in Cardiovascular Disorders |
| Q37167471 | Rap1-mediated nuclear factor-kappaB (NF-κB) activity regulates the paracrine capacity of mesenchymal stem cells in heart repair following infarction |
| Q92578413 | Rapamycin-Preactivated Autophagy Enhances Survival and Differentiation of Mesenchymal Stem Cells After Transplantation into Infarcted Myocardium |
| Q64991457 | Re-Defining Stem Cell-Cardiomyocyte Interactions: Focusing on the Paracrine Effector Approach. |
| Q39076891 | Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics. |
| Q35459559 | Re-modelling 'hostile' milieu of diseased myocardium via paracrine function of transplanted cells or relaxin |
| Q38874116 | Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue. |
| Q35070251 | Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease |
| Q52657125 | Recent Progress in Stem Cell Modification for Cardiac Regeneration. |
| Q36083407 | Recent Progress on Chemical Biology of Pluripotent Stem Cell Self-renewal, Reprogramming and Cardiomyogenesis |
| Q26739985 | Recent Stem Cell Advances: Cord Blood and Induced Pluripotent Stem Cell for Cardiac Regeneration- a Review |
| Q52782743 | Recovery of renal function after administration of adipose-tissue-derived stromal vascular fraction in rat model of acute kidney injury induced by ischemia/reperfusion injury. |
| Q33764626 | Reduction of Na/K-ATPase affects cardiac remodeling and increases c-kit cell abundance in partial nephrectomized mice. |
| Q27687840 | Regenerating functional heart tissue for myocardial repair |
| Q64065918 | Regenerative Cardiovascular Therapies: Stem Cells and Beyond |
| Q38075104 | Regenerative medicine for the treatment of heart disease |
| Q37821376 | Regenerative therapies in electrophysiology and pacing: introducing the next steps |
| Q38174769 | Regenerative therapy for cardiovascular disease |
| Q35050037 | Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. |
| Q37104058 | Repairing damaged myocardium: evaluating cells used for cardiac regeneration |
| Q36278420 | Repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial |
| Q92405265 | Reproducibility of GMP-compliant production of therapeutic stressed peripheral blood mononuclear cell-derived secretomes, a novel class of biological medicinal products |
| Q26800082 | Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand? |
| Q38269487 | Rethinking regenerative medicine: a macrophage-centered approach |
| Q37766134 | Review of stem cell-based therapy for the treatment of cardiovascular disease |
| Q37976449 | Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells |
| Q36294424 | Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart |
| Q41940674 | Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis |
| Q54561835 | S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt. |
| Q92618217 | SDF-1α promotes repair of myocardial ischemic necrosis zones in rats |
| Q35009602 | SDF-1α secreted by human CD133-derived multipotent stromal cells promotes neural progenitor cell survival through CXCR7 |
| Q30563310 | SLIT3-ROBO4 activation promotes vascular network formation in human engineered tissue and angiogenesis in vivo |
| Q30428262 | Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy |
| Q28587325 | Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair |
| Q37260268 | Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a |
| Q48602794 | Secretome of Aggregated Embryonic Stem Cell-Derived Mesenchymal Stem Cell Modulates the Release of Inflammatory Factors in Lipopolysaccharide-Induced Peripheral Blood Mononuclear Cells |
| Q36233665 | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation |
| Q21133599 | Secretome of peripheral blood mononuclear cells enhances wound healing |
| Q37035997 | Serum-deprived human multipotent mesenchymal stromal cells (MSCs) are highly angiogenic |
| Q33892777 | Simvastatin augments the efficacy of therapeutic angiogenesis induced by bone marrow-derived mesenchymal stem cells in a murine model of hindlimb ischemia |
| Q37054555 | Skeletal myoblasts and cardiac repair |
| Q30273656 | Sonic Hedgehog gene delivery to the rodent heart promotes angiogenesis via iNOS/netrin-1/PKC pathway |
| Q38798555 | Stem Cell Extracellular Vesicles: Extended Messages of Regeneration |
| Q39124190 | Stem Cell Technology in Cardiac Regeneration: A Pluripotent Stem Cell Promise |
| Q38992231 | Stem Cell Therapy for Myocardial Infarction 2001-2013 Revisited |
| Q28069300 | Stem Cell Therapy for the Heart: Blind Alley or Magic Bullet? |
| Q85240790 | Stem and progenitor cell-based therapy approaches: current developments on treatment of acute myocardial infarction and chronic ischemic cardiomyopathy |
| Q35462023 | Stem cell conditioned culture media attenuated albumin-induced epithelial-mesenchymal transition in renal tubular cells |
| Q36494604 | Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action |
| Q37545373 | Stem cell death and survival in heart regeneration and repair |
| Q37045472 | Stem cell differentiation: cardiac repair |
| Q35002029 | Stem cell factor gene transfer improves cardiac function after myocardial infarction in swine |
| Q33708216 | Stem cell paracrine actions and tissue regeneration |
| Q26740531 | Stem cell procedures in arthroscopic surgery |
| Q38098219 | Stem cell stimulation of endogenous myocyte regeneration |
| Q37087315 | Stem cell therapies in cardiovascular disease A "realistic" appraisal. |
| Q37827158 | Stem cell therapy for cardiac disease. |
| Q37544884 | Stem cell therapy for cardiac repair: benefits and barriers |
| Q26827498 | Stem cell therapy for incontinence: where are we now? What is the realistic potential? |
| Q38761212 | Stem cell therapy for ischemic heart diseases |
| Q36368239 | Stem cell transplantation for the treatment of myocardial infarction |
| Q37166081 | Stem cell use for cardiac diseases as of 2008. |
| Q37900227 | Stem cell-based cardiac tissue engineering |
| Q28071466 | Stem cell-derived exosomes as a therapeutic tool for cardiovascular disease |
| Q37766151 | Stem cells and cardiac repair: a critical analysis |
| Q37991771 | Stem cells and regenerative medicine - future perspectives |
| Q37688435 | Stem cells for myocardial repair with use of a transarterial catheter |
| Q36446920 | Stem cells for the ischaemic heart |
| Q37766200 | Stem cells in the infarcted heart |
| Q57767168 | Stem-Cell-Based Therapies for Vascular Regeneration in Peripheral Artery Diseases |
| Q37164041 | Stem-cell-based therapy and lessons from the heart |
| Q28068007 | Strategies and Challenges to Myocardial Replacement Therapy |
| Q34795299 | Strategies for cardiac regeneration and repair |
| Q38938850 | Strategies for functional bioscaffold-based skeletal muscle reconstruction |
| Q37162061 | Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation |
| Q37318040 | Stretching the limits: stem cells in regeneration science |
| Q94545341 | Substance P Improves Renal Ischemia Reperfusion Injury Through Modulating Immune Response |
| Q53258151 | Sustained IGF-1 Secretion by Adipose-Derived Stem Cells Improves Infarcted Heart Function. |
| Q52724942 | Sustained Release of Endothelial Progenitor Cell-Derived Extracellular Vesicles from Shear-Thinning Hydrogels Improves Angiogenesis and Promotes Function after Myocardial Infarction. |
| Q41996348 | Synergism of matrix stiffness and vascular endothelial growth factor on mesenchymal stem cells for vascular endothelial regeneration |
| Q45856327 | Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. |
| Q34784627 | TGF-β2 treatment enhances cytoprotective factors released from embryonic stem cells and inhibits apoptosis in infarcted myocardium |
| Q33769592 | TLR4 inhibits mesenchymal stem cell (MSC) STAT3 activation and thereby exerts deleterious effects on MSC-mediated cardioprotection |
| Q37089726 | Tackling heart failure in the twenty-first century |
| Q38697049 | Taking a bite out of spinal cord injury: do dental stem cells have the teeth for it? |
| Q36642702 | Targeting angiogenesis versus myogenesis with cardiac cell therapy |
| Q37220758 | Targeting human CD34+ hematopoietic stem cells with anti-CD45 x anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction |
| Q41248205 | Telocytes - a Hope for Cardiac Repair after Myocardial Infarction |
| Q35558497 | Terminal differentiation is not a major determinant for the success of stem cell therapy - cross-talk between muscle-derived stem cells and host cells |
| Q46718093 | Testing the Paracrine Properties of Human Mesenchymal Stem Cells Using Conditioned Medium. |
| Q26769042 | The Evolution of the Stem Cell Theory for Heart Failure |
| Q40988293 | The Healing Effect of Conditioned Media and Bone Marrow-Derived Stem Cells in Laryngotracheal Stenosis: A Comparison in Experimental Dog Model |
| Q92128776 | The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity |
| Q41553531 | The Impact of Confluence on Bone Marrow Mesenchymal Stem (BMMSC) Proliferation and Osteogenic Differentiation |
| Q58719281 | The Importance of Biophysical and Biochemical Stimuli in Dynamic Skeletal Muscle Models |
| Q36995514 | The Necessity of a Systematic Approach for the Use of MSCs in the Clinical Setting |
| Q27004398 | The Regenerative Role of the Fetal and Adult Stem Cell Secretome |
| Q28080565 | The Role of MicroRNAs in Cardiac Stem Cells |
| Q64925846 | The Therapeutic Potential of Stem Cells for Bronchopulmonary Dysplasia: "It's About Time" or "Not so Fast" ? |
| Q48653172 | The Use of Biocompatible Alginate Scaffolds Covalently Modified with Cyclic RGDfK Peptides to Improve Survival of Transplanted Cells and Angiogenesis in Damaged Myocardium |
| Q37293743 | The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning |
| Q36836344 | The birth of 'regenerative pharmacology': a clinical perspective |
| Q98291533 | The clinical application of mesenchymal stem cells in liver disease: the current situation and potential future |
| Q41864818 | The effects of adenoviral transfection of the keratinocyte growth factor gene on epidermal stem cells: an in vitro study |
| Q28570440 | The effects of mesenchymal stem cells on c-kit up-regulation and cell-cycle re-entry of neonatal cardiomyocytes are mediated by activation of insulin-like growth factor 1 receptor |
| Q35584038 | The effects of secretion factors from umbilical cord derived mesenchymal stem cells on osteogenic differentiation of mesenchymal stem cells. |
| Q40348066 | The future of cell therapy for acute myocardial infarction |
| Q36850913 | The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo |
| Q44113705 | The importance of understanding the molecular mechanism of stem cell-induced cardiac tissue repair |
| Q34257083 | The influence of autologous bone marrow stem cell transplantation on matrix metalloproteinases in patients treated for acute ST-elevation myocardial infarction |
| Q37766123 | The paracrine effect: pivotal mechanism in cell-based cardiac repair |
| Q90115342 | The proangiogenic effects of extracellular vesicles secreted by dental pulp stem cells derived from periodontally compromised teeth |
| Q37594948 | The role of bioactive lipids in stem cell mobilization and homing: novel therapeutics for myocardial ischemia |
| Q35861681 | The role of immunosuppression of mesenchymal stem cells in tissue repair and tumor growth |
| Q37306210 | The role of progenitor cells in the development of intimal hyperplasia |
| Q37067647 | The role of stem cells in the post-MI patient |
| Q38274270 | The role of tissue engineering and biomaterials in cardiac regenerative medicine |
| Q36897375 | The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy |
| Q36740266 | The use of scaffold-free cell sheet technique to refine mesenchymal stromal cell-based therapy for heart failure. |
| Q59807954 | Therapeutic Effect of Human Umbilical Cord Mesenchymal Stem Cells at Various Passages on Acute Liver Failure in Rats |
| Q47935765 | Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes in Cardiovascular Disease |
| Q64062508 | Therapeutic Potential of Extracellular Vesicles for the Treatment of Nerve Disorders |
| Q47763374 | Therapeutic Potential of Hematopoietic Stem Cell-Derived Exosomes in Cardiovascular Disease. |
| Q35823993 | Therapeutic Potential of Stem Cells from Human Exfoliated Deciduous Teeth in Models of Acute Kidney Injury |
| Q38841567 | Therapeutic angiogenesis: angiogenic growth factors for ischemic heart disease |
| Q95360896 | Therapeutic applications of adipose-derived stem cells in cardiovascular disease |
| Q41933891 | Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. |
| Q36395705 | Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair |
| Q26779938 | Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy |
| Q36909360 | Therapeutic potential of adult progenitor cells in cardiovascular disease |
| Q94663995 | Therapeutic potential of lipids obtained from γ-irradiated PBMCs in dendritic cell-mediated skin inflammation |
| Q38031213 | Therapeutic potential of mesenchymal stem cell-derived microvesicles. |
| Q38857237 | Tissue Engineering Strategies for Myocardial Regeneration: Acellular Versus Cellular Scaffolds? |
| Q38167702 | Tissue engineering and regenerative medicine approaches to enhance the functional response to skeletal muscle injury |
| Q33537670 | Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling |
| Q33840741 | Toll-like receptor 2 mediates mesenchymal stem cell-associated myocardial recovery and VEGF production following acute ischemia-reperfusion injury |
| Q64082706 | Toxicological testing of allogeneic secretome derived from peripheral mononuclear cells (APOSEC): a novel cell-free therapeutic agent in skin disease |
| Q35665292 | Tracking fusion of human mesenchymal stem cells after transplantation to the heart |
| Q27438164 | Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes |
| Q26774565 | Translational research of adult stem cell therapy |
| Q49875736 | Transplantation of Allogeneic Pericytes Improves Myocardial Vascularization and Reduces Interstitial Fibrosis in a Swine Model of Reperfused Acute Myocardial Infarction. |
| Q50637278 | Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction. |
| Q51842282 | Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. |
| Q36294602 | Transplantation of cord blood mesenchymal stem cells as spheroids enhances vascularization |
| Q36757074 | Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132 |
| Q51105200 | Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. |
| Q46139780 | Transplantation of mesenchymal stem cells improves atrioventricular conduction in a rat model of complete atrioventricular block |
| Q47848637 | Transplantation of mesenchymal stem cells overexpressing IL10 attenuates cardiac impairments in rats with myocardial infarction |
| Q44828167 | Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction |
| Q52886470 | Treatment of dilated cardiomyopathy in rabbits with mesenchymal stem cell transplantation and platelet-rich plasma. |
| Q39772665 | Treatment of pulmonary arterial hypertension with circulating angiogenic cells |
| Q35731055 | Treatment with hESC-Derived Myocardial Precursors Improves Cardiac Function after a Myocardial Infarction |
| Q92096728 | Triple-marker cardiac MRI detects sequential tissue changes of healing myocardium after a hydrogel-based therapy |
| Q37512338 | Trophic actions of bone marrow-derived mesenchymal stromal cells for muscle repair/regeneration |
| Q43166311 | Unraveling the mechanistic basis of mesenchymal stem cell activity in the heart |
| Q27003127 | Use of mesenchymal stem cells for therapy of cardiac disease |
| Q35114758 | VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart |
| Q28567683 | VEGFR1/CXCR4-positive progenitor cells modulate local inflammation and augment tissue perfusion by a SDF-1-dependent mechanism |
| Q37451512 | Vascular stem cells-potential for clinical application |
| Q37824871 | Very small embryonic-like stem cells: biology and therapeutic potential for heart repair |
| Q43203972 | What is the oncologic risk of stem cell treatment for heart disease? |
| Q55069122 | [Prediction of the molecular response to pertubations from single cell measurements]. |
| Q41370575 | microRNA and Cardiac Regeneration. |
| Q91596421 | microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential |
| Q34163289 | shRNA-mediated decreases in c-Met levels affect the differentiation potential of human mesenchymal stem cells and reduce their capacity for tissue repair |
Search more.